Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Change in Accured Expenses (2021 - 2025)

Prime Medicine (PRME) has disclosed Change in Accured Expenses for 5 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 1211.11% year-over-year to $1.6 million, compared with a TTM value of -$1.2 million through Dec 2025, down 162.94%, and an annual FY2025 reading of -$1.2 million, down 162.94% over the prior year.
  • Change in Accured Expenses was $1.6 million for Q4 2025 at Prime Medicine, up from -$1.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $33.3 million in Q4 2021 and bottomed at -$33.3 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $581058.8, with a median of $890000.0 recorded in 2022.
  • Peak annual rise in Change in Accured Expenses hit 1211.11% in 2025, while the deepest fall reached 118.06% in 2025.
  • Year by year, Change in Accured Expenses stood at $33.3 million in 2021, then crashed by 87.73% to $4.1 million in 2022, then tumbled by 38.53% to $2.5 million in 2023, then tumbled by 105.73% to -$144000.0 in 2024, then surged by 1211.11% to $1.6 million in 2025.
  • Business Quant data shows Change in Accured Expenses for PRME at $1.6 million in Q4 2025, -$1.1 million in Q3 2025, and $5.0 million in Q2 2025.